تحميل...
Renal allograft rejection after treatment with nivolumab in patients with metastatic renal cell carcinoma
In recent years, immune checkpoint inhibitors (ICIs), such as nivolumab, pembrolizumab and ipilimumab, have been introduced into routine clinical practice for treating patients with several types of advanced cancer, including renal cell carcinoma (RCC). However, activation of the immune system again...
محفوظ في:
| الحاوية / القاعدة: | Int Cancer Conf J |
|---|---|
| المؤلفون الرئيسيون: | , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
Springer Singapore
2021
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7947052/ https://ncbi.nlm.nih.gov/pubmed/33786286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13691-020-00458-8 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|